rheumatoid%20arthritis
RHEUMATOID ARTHRITIS

Rheumatoid arthritis is a systemic autoimmune rheumatic disorder of unknown etiology.
It is the most common form of inflammatory arthritis.
Patient usually complains of joint pain and/or swelling with morning stiffness that lasts for more than an hour.

Goals of treatment are clinical & radiological remission of disease and to reduce functional limitations & permanent joint damage.

Follow Up

Monitoring for Drug Toxicity

  • Eg complete blood count, serum creatinine, liver function tests, hepatitis B & C screening, ophthalmologic exam, latent tuberculosis screening (for biological DMARDs, with chest X-ray)
  • Recommended prior to resuming or increasing therapy with DMARDs
  • It is important to monitor for toxicity due to the potential risks of serious adverse effects of DMARDs

Tapering of Therapy

  • Should be considered if there is disease remission with biological DMARDs therapy of at least 6 months
    • Glucocorticoid dose should be tapered first prior to reduction of dose of biological DMARDs
  • To decrease risk of flares, gradual withdrawal of biological therapies should be done
    • Flare risk is inversely proportional to disease activity & sustained response duration
  • In persistent remission of at least 12 months, biological DMARDs should be slowly tapered by expanding the interval between doses or dose reduction, while continuing non-biological DMARDs
  • Ceasing treatment with non-biological DMARDs is associated with increased flare frequency, hence tapering should be done cautiously & should be evaluated rigorously

Disease Activity Monitoring

  • Disease activity should be measured & documented regularly
    • Moderate-high disease activity: monthly
    • Sustained low disease activity: every 6 months
    • Clinical remission: every 6 months (with DAS & DAS28)
    • Sustained remission: every 3-6 months
  • Consider structural changes, comorbidities, & functional impairment when formulating treatment decisions on follow-ups
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
04 Feb 2019
The carbon-chain length of saturated fatty acids appears to be an important factor in determining its role in cardiovascular health, a recent study has found.
6 days ago
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
Pearl Toh, 3 days ago
A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.
Jairia Dela Cruz, 04 Feb 2019
Treatment with secukinumab results in a higher rate of remission or low-disease activity at week 16 in patients with psoriatic arthritis as compared with placebo, according to a posthoc analysis of the FUTURE 2 study. This effect is sustained at 2 years and is evident in both tumour necrosis factor inhibitor-experienced and -naïve patients.